Influência do alendronato e ranelato de estrôncio na reparação de alvéolos pós extração e na progressão/tratamento da periodontite: estudo em ratos
Carregando...
Data
2022-04-01
Autores
Gonçalves, Fernanda Castanheira
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
O objetivo foi avaliar o efeito preventivo da administração do Ranelato de Estrôncio sobre o processo de osteonecrose induzida por bisfosfonatos, e o efeito do alendronato e estrôncio na modulação da doença periodontal experimental. Na avaliação da influência do estrôncio na osteonecrose induzida por bisfosfonato, foram utilizados 60 ratos, divididos em 6 grupos: Grupo CTR –administração de soro fisiológico diária por 60 dias, posteriormente foi realizada cirurgia para extração dos primeiros molares inferiores, e continuação da aplicação de soro por mais 30 dias; Grupo ALN – administração alendronato de sódio (1 mg/kg/dia) durante 60 dias antes da extração dentária e a mesma foi continuada por 30 dias; Grupo ALN/S –administração de alendronato por 60 dias e feita a extração, continuação de soro por 30 dias; Grupo ALN/STR –alendronato durante 60 dias e posteriormente foi interrompida a sua administração por 30 dias previamente a extração. Em seguida a extração, foi administrado o ranelato de estrôncio por 30 dias (625 mg/kg/dia); Grupo ALN/S60– alendronato foi administrado por 60 dias e sua administração interrompida por 30 dias até o momento da extração. Posteriormente, foi administrado soro por mais 30 dias após a cirurgia.; Grupo ALN/STR 60 – administração alendronato por 60 dias, após esse período a administração do alendronato foi interrompida e iniciado o ranelato de estrôncio, por 30 dias. Após esse período os dentes foram extraídos e a aplicação do ranelato de estrôncio foi continuada por mais 30 dias. Foram realizadas análises microtomográfica, análises histológica/estereométrica e histológicas. Os resultados mostraram uma melhora nos efeitos colaterais da osteonecrose por bisfosfonatos nos grupos em que foram administrados estrôncio, mesmo na presença de tecido necrótico ocorreu a formação da matriz de tecido ósseo na porção basal dos alvéolos. Para avaliar a progressão da doença periodontal foram utilizados 21 ratos, divididos em 3 grupos: Grupo CTR – administração de soro fisiológico subcutânea diariamente; Grupo ALD – administração de alendronato de sódio (1 mg/kg/dia); Grupo STR – administração de ranelato de estrôncio (625 mg/kg/dia. Em todos os grupos os medicamentos foram administrados durante 60 dias, sendo que após 45 dias de início da administração foram colocadas ligaduras nos segundos molares superiores. Para avaliar a influência desses medicamentos no tratamento da doença periodontal foram utilizados 42 animais que foram divididos em 3 grupos, cada grupo com 2 sub-grupos cada (7 animais em cada sub-grupo; n=14 ligaduras/sub-grupo) de acordo com o seguinte protocolo: 1) Controle (CTR), indução da doença periodontal e administração de soro fisiológico 1 mg/kg/dia até o momento da eutanásia. 2) Alendronato (ALD), indução da DP por 15 dias, juntamente com a administração diária bisfosfonato 1 mg/kg/dia até o momento da eutanásia. 3) Estrôncio (STR), indução da DP e administração diária de Ranelato de Estrôncio aplicado 625 mg/kg/dia por gavagem até o momento da eutanásia. Cada grupo teve 2 sub-grupos onde o subgrupo RR recebeu tratamento periodontal após a indução da DP e o subgrupo NR os animais não receberam nenhum tipo de tratamento. Os animais foram eutanasiados nos períodos de 7, 15 e 30 dias. Em ambos os estudos foram realizadas análises microtomográfica, histológica, histométrica, estereométrica. Foi observado que os medicamentos não impediram o aparecimento da doença periodontal. O ALN foi capaz de minimizar a perda óssea alveolar, porém nas regiões interproximais tinham pequenas áreas de tecido necrótico, já os animais tratados com STR continham uma maior área de tecido de reparação, matriz de tecido conjuntivo, fibras colágenas organizadas e matriz osteóide. O ALD e o STR influenciaram na modulação da periodontite, ALD diminuindo a perda óssea alveolar e o STR aumentando o tecido de reparação nas áreas em que ocorreu reabsorção óssea.
The objective was to evaluate the preventive effect of the administration of strontium ranelate on the process of bisphosphonate-induced osteonecrosis, and the effect of alendronate and strontium on the modulation of experimental periodontal disease. 60 lower rats, divided into 6 groups: Group saline solution for 60 days, administered later to the lower first molars, and continuation of the saline operation for another 30 days; ALN group – alendronate drug administration (1 mg/kg/day) for 60 days before collection and continued for 30 days; ALNS group – administration of alendronate for 60 days and done at 30, continuation of serum for 60 days; Group ALN/STR – alendronate 60 days and 30 days later, its administration was interrupted for 60 days prior to a collection. After receiving, strontium ranelate was administered for 30 days (625 mg/kg/day); Group ALN /S60– alendronate was administered for 60 days and its administration for 30 days until the moment of reception. Subsequently, it was administered for an additional 30 days after surgery.; ALN/Sr 60 group – alendronate administration for 60 days, after which alendronate administration was started and strontium ranelate was started for 30 days. After this period, the teeth were extracted and the application of strontium ranelate was continued for another 30 days. Microtomographic, histological/stereometric and histological analyzes were performed. Osteonecrosis effects an improvement in the beneficial effects of bisphosphonates, even in the formation of bone tissue matrix in the basal portion of necrotic tissues. To evaluate the progression of periodontics, 21 rats were used, the disease was concentrated in 3 groups: Group subcutaneous saline daily; ALD group – administration of drug alendronate (1 mg/kg/day); STR group – administration of rancid strontium 25 mg/kg/day. In all groups, the drugs were administered for 60 days, and after 4 days of starting administration there were 45 days of starting administration, there were 4 connections prior to these second molars. To evaluate the influence of Medications in the treatment of periodontics, 42 animals were used which were resolved into 3 groups, each group with 2 subgroups each (7 animals in each subgroup; 7 animals in each subgroup; 14 ligatures/subgroup) according to the following protocol: 1) Control of periodontal disease and administration of saline solution 1 mg/kg/day until the moment of euthanasia. 1 mg/kg/day 2 days, ALD, A Phosphonate, with daily administration up to 1 mg/kg/day. 3) Strontium (STR), PD induction and daily administration of Strontium ranelate applied 625 mg/kg/day by gavage until the time of euthanasia. Each group had 2 subgroups where the RR subgroup received periodontal treatment after PD induction and the NR subgroup the animals did not receive any type of treatment. The animals were euthanized at 7, 15 and 30 days. In both studies, microtomographic, histometric and stereometric views were performed. It was observed that the drugs did not prevent the onset of periodontal disease. The ALN was able to minimize alveolar loss, but the interproximal regions had areas of alveolar tissue, whereas the animals treated with larger STRs contained an area of connective tissue, small matrix, organized bone fibers. OLD and STR influenced bone loss, ALD modulation of bone injury and increased alveolar tissue in areas where resorption occurred.
The objective was to evaluate the preventive effect of the administration of strontium ranelate on the process of bisphosphonate-induced osteonecrosis, and the effect of alendronate and strontium on the modulation of experimental periodontal disease. 60 lower rats, divided into 6 groups: Group saline solution for 60 days, administered later to the lower first molars, and continuation of the saline operation for another 30 days; ALN group – alendronate drug administration (1 mg/kg/day) for 60 days before collection and continued for 30 days; ALNS group – administration of alendronate for 60 days and done at 30, continuation of serum for 60 days; Group ALN/STR – alendronate 60 days and 30 days later, its administration was interrupted for 60 days prior to a collection. After receiving, strontium ranelate was administered for 30 days (625 mg/kg/day); Group ALN /S60– alendronate was administered for 60 days and its administration for 30 days until the moment of reception. Subsequently, it was administered for an additional 30 days after surgery.; ALN/Sr 60 group – alendronate administration for 60 days, after which alendronate administration was started and strontium ranelate was started for 30 days. After this period, the teeth were extracted and the application of strontium ranelate was continued for another 30 days. Microtomographic, histological/stereometric and histological analyzes were performed. Osteonecrosis effects an improvement in the beneficial effects of bisphosphonates, even in the formation of bone tissue matrix in the basal portion of necrotic tissues. To evaluate the progression of periodontics, 21 rats were used, the disease was concentrated in 3 groups: Group subcutaneous saline daily; ALD group – administration of drug alendronate (1 mg/kg/day); STR group – administration of rancid strontium 25 mg/kg/day. In all groups, the drugs were administered for 60 days, and after 4 days of starting administration there were 45 days of starting administration, there were 4 connections prior to these second molars. To evaluate the influence of Medications in the treatment of periodontics, 42 animals were used which were resolved into 3 groups, each group with 2 subgroups each (7 animals in each subgroup; 7 animals in each subgroup; 14 ligatures/subgroup) according to the following protocol: 1) Control of periodontal disease and administration of saline solution 1 mg/kg/day until the moment of euthanasia. 1 mg/kg/day 2 days, ALD, A Phosphonate, with daily administration up to 1 mg/kg/day. 3) Strontium (STR), PD induction and daily administration of Strontium ranelate applied 625 mg/kg/day by gavage until the time of euthanasia. Each group had 2 subgroups where the RR subgroup received periodontal treatment after PD induction and the NR subgroup the animals did not receive any type of treatment. The animals were euthanized at 7, 15 and 30 days. In both studies, microtomographic, histometric and stereometric views were performed. It was observed that the drugs did not prevent the onset of periodontal disease. The ALN was able to minimize alveolar loss, but the interproximal regions had areas of alveolar tissue, whereas the animals treated with larger STRs contained an area of connective tissue, small matrix, organized bone fibers. OLD and STR influenced bone loss, ALD modulation of bone injury and increased alveolar tissue in areas where resorption occurred.
Descrição
Palavras-chave
Osteonecrose, Alendronato, Estrôncio, Extração dentária, Periodontite, Osteonecrosis, Alendronate, Strontium Ranelate, Tooth Extraction, Periodontitis